MRI of Fascial Structures — Generic Standard Protocol

MRI of Fascial Structures — Generic Standard Protocol

MRIninja Knowledge Base | Master / General Protocol Page Anatomical domain: superficial and deep fasciae, aponeuroses, and intermuscular septa — a cross-regional generic reference page, applicable across all body districts Version 1.0 — August 2026

1. Executive Summary

The fascial system is a continuous, body-wide network of dense connective tissue — superficial (subcutaneous) fascia, deep (investing) fascia, intermuscular septa, and aponeuroses — that has historically received far less imaging attention than the muscle, bone, and joint structures it envelops and separates [1]. This is a genuine blind spot: the same fascial planes that are largely inert in health become the decisive anatomical substrate in a wide range of traumatic, infective, inflammatory/autoimmune, and neoplastic conditions, and their involvement — or lack of it — frequently determines management more than the adjacent muscle or bone findings do [2].

MRI is the reference-standard modality for fascial imaging because it is the only widely available technique that reliably depicts the fascial planes themselves, rather than inferring their involvement indirectly from adjacent soft-tissue change [1,2]. Ultrasound can assess superficial fascia and is a reasonable first-line triage tool for accessible, localized abnormalities, but its performance falls off for deep fascial planes, for compartments obscured by gas or bone, and for full-extent mapping along a fascial plane that may travel well beyond the clinically evident abnormality; CT retains a defined role where gas detection, calcification, or a contraindication to MRI dominates the clinical question, but its soft-tissue contrast for fascia itself is inferior to MRI's [2].

This generic master page establishes the technical and interpretive backbone shared by the four major disease categories in which fascial imaging is clinically decisive:

• Traumatic/mechanical — Morel-Lavallée lesion (post-traumatic closed degloving injury with a shear-plane fluid collection between the deep fascia and subcutaneous fat), myo-aponeurotic and myotendinous junction injuries, and muscle herniation through a fascial defect [1].
• Infective — necrotizing and non-necrotizing cellulitis/fasciitis, pyomyositis with secondary fascial involvement, and post-surgical or post-traumatic fascial infection [1].
• Inflammatory/autoimmune — localized scleroderma (morphea), eosinophilic fasciitis, and fascial involvement in systemic sclerosis and other connective tissue diseases, in which the deep fascia is frequently the dominant or even the exclusive site of MRI abnormality [3].
• Neoplastic — superficial fibromatosis, desmoid-type fibromatosis, and fascia-based or fascia-invading sarcomas [1].

These four categories share a near-identical acquisition backbone — multiplanar fluid-sensitive fat-suppressed sequences as the primary detection tool, a non-fat-suppressed T1-weighted sequence as the anatomical/fat-content baseline, and a central (though not universally mandatory) role for gadolinium-enhanced fat-suppressed T1 imaging once infection, active inflammation, or a mass is suspected — which is what justifies grouping them on a single generic master page rather than duplicating the same technical backbone across every organ-specific protocol on this platform. Their downstream management pathways diverge sharply once a specific diagnosis is suspected, which is why this page is explicitly designed to route toward dedicated pathology-specific child pages rather than to provide definitive diagnostic criteria for any single entity.

This generic protocol is designed to answer the broad first-line question: "is the fascia itself abnormal, and if so, what is the pattern (thickening, signal change, enhancement, fluid, gas) and its distribution?" It is explicitly not designed to:

• provide validated, entity-specific diagnostic criteria for any individual fascial pathology (these are the province of the dedicated child pages, e.g. necrotizing fasciitis, eosinophilic fasciitis, Morel-Lavallée lesion);
• substitute for emergency clinical and surgical assessment when the clinical picture already suggests a necrotizing or rapidly progressive infective process — this remains fundamentally a surgical emergency, and imaging, at any stage, must never delay surgical exploration or referral;
• replace the organ/region-specific master protocols on this platform (e.g., the muscle-trauma, muscle-tumour/infection, or region-specific joint masters) for indications where the fascia is not the primary structure of clinical concern;
• provide a histological or microbiological diagnosis — tissue/fluid sampling remains the reference standard wherever the generic imaging pattern is not itself sufficiently specific.

1.1 Core Strengths

• Fluid-sensitive fat-suppressed sequences depict fascial thickening, oedema, and fluid with a sensitivity that no other routinely available modality matches, which is precisely why MRI — not CT or ultrasound — is the reference standard whenever a fascia-centred process is genuinely in the differential [2].
• Multiplanar acquisition allows a fascial plane to be traced along its full course, which is essential given that fascial disease — infective, inflammatory, or neoplastic — frequently extends well beyond the area of clinically visible abnormality.
• Gadolinium-enhanced fat-suppressed T1 imaging discriminates viable, hyperaemic fascia (which enhances) from necrotic or avascular fascia (which does not), the single most consequential distinction across the infective and inflammatory categories on this page.
• The normal fascial system has a distinctive, low-signal-intensity, thin reticular baseline appearance on both T1- and fluid-sensitive sequences, embedded in and often nearly indistinguishable from adjacent fat on fat-suppressed images [3]; this consistent baseline is itself diagnostically useful, since almost any visible deviation from it (thickening, distinct fluid-signal intensity, abnormal enhancement) is a meaningful finding rather than incidental noise.

1.2 Intrinsic Limitations of the Generic Protocol

• The normal fascia is intrinsically difficult to visualise. The fascia superficialis appears as a thin reticular network of low signal intensity on T1- and T2-weighted sequences, embedded in hypodermic fat, and becomes even less conspicuous — sometimes nearly indistinguishable from suppressed fat — on fluid-sensitive fat-suppressed sequences; the deep peripheral fascia is only reliably depicted where fat is present immediately deep to it [3]. A generic protocol optimised purely for fascial conspicuity can therefore under-perform for concurrent muscle or bone pathology, and vice versa — protocol prioritisation should be explicit rather than assumed.
• MRI abnormality of the fascia is sensitive but rarely, by itself, entity-specific. Thickening, oedema-type signal, and enhancement are shared, in overlapping proportions, across trauma, infection, inflammation, and neoplasia; the generic pattern described on this page is a starting point for a differential, not a diagnostic algorithm, and entity-specific discriminators (thresholds, distribution patterns, enhancement subtype) belong to the dedicated child pages.
• Time-critical infective presentations must not be delayed by elective-style imaging workflow. When the clinical picture already strongly suggests a necrotizing process, imaging — if performed at all — must be expedited and must never substitute for, or delay, surgical exploration and referral.
• A generic field of view centred on the point of maximal clinical concern may under-sample longitudinal disease extent. Fascial disease of every category on this page — infective tracking, inflammatory/autoimmune involvement, and neoplastic spread along an aponeurotic plane — is characteristically capable of extending well beyond the palpable or visibly abnormal segment; FOV planning specific to fascial imaging (Section 4.6) addresses this directly.
• Contrast is central to several, but not all, of the four disease categories on this page (particularly infective and neoplastic disease), while being frequently unnecessary for straightforward traumatic/mechanical indications (e.g., an uncomplicated Morel-Lavallée lesion); the decision belongs to the specific clinical question, not to a single protocol default (Section 6).

2. Main Clinical Indications

2.1 Standard Indications

A generic fascia-directed MRI study, or a study in which fascial assessment is a co-primary objective alongside adjacent muscle/soft-tissue evaluation, is appropriate for: a palpable band-like or plate-like soft-tissue abnormality following the expected course of a named fascial structure; unexplained regional pain or swelling with a normal or only secondarily abnormal adjacent muscle and bone examination; suspected closed degloving (shear-plane) injury following blunt trauma, particularly over the greater trochanter, lateral thigh, knee, or lumbosacral region, where a Morel-Lavallée lesion is a recognised entity; suspected fascial or fascial/muscular infection where the depth and longitudinal extent of involvement is unclear on clinical examination or ultrasound; new or progressive skin/subcutaneous tightening, induration, or a "groove sign" suggestive of localized scleroderma or a systemic sclerosis-spectrum disease, where deep fascial thickening and enhancement is frequently the dominant, sometimes the only, MRI-visible abnormality [3]; and a palpable, slowly growing, non-tender soft-tissue mass following a fascial or aponeurotic plane, raising concern for superficial fibromatosis, desmoid-type fibromatosis, or a fascia-based sarcoma.

2.2 Urgent Red Flags Requiring Expedited or Emergency Imaging

3. Preparation Reference

Universal MRI safety screening (implants, devices, claustrophobia) and the universal gadolinium contrast safety questionnaire belong to the general MRI preparation page and are not repeated here in full.

3.1 Topic-Specific Preparation Items

• Region is determined by the clinical question, not by a fixed anatomical default: unlike an organ-specific master page, this protocol has no single body region; the referrer's clinical localisation of the abnormality (palpable finding, imaging trigger from prior ultrasound/CT, or documented site of trauma) determines coil selection, patient positioning, and FOV planning, and must be confirmed before the patient is positioned.
• Skin marker at the point of maximal clinical concern: essential for correct FOV centring; arguably more important here than for most organ-specific protocols, since fascial abnormality frequently extends beyond, and is occasionally displaced from, the area of visible skin change.
• Documentation of trauma mechanism, prior biopsy/aspiration, or surgical intervention at the site: post-traumatic, post-biopsy, and post-surgical change materially alter fascial signal and enhancement and must be known before the study is read.
• Contralateral comparison should be anticipated at planning: fascial thickness, signal, and enhancement are frequently interpreted by comparison with the unaffected side, particularly for suspected inflammatory/autoimmune disease and for subtle infective change; symmetric coverage should be planned proactively rather than added as an afterthought.
• Renal function / GBCA eligibility screening should be anticipated at referral whenever the clinical question includes infection, inflammation, or a mass, since contrast is very likely to be required (Section 6).
• Patient history that changes the protocol: known autoimmune/connective tissue disease (raises pre-test probability of an inflammatory fascial pattern and may prompt a bilateral comparative protocol); immunosuppression or diabetes (raises the threshold of concern for an aggressive or necrotizing infective process); recent blunt trauma to a shear-prone region (raises pre-test probability of a Morel-Lavallée lesion); known malignancy elsewhere (raises pre-test probability of a fascia-invading secondary process).

3.2 Patient Positioning on the MRI System

• Position: dictated by the region under investigation; no single default applies across this cross-regional protocol.
• Coil selection and centring: flexible surface/phased-array coils for limb and superficial trunk lesions; body/torso coil combinations for large or deep trunk lesions; coverage should extend generously along the long axis of the suspected fascial plane, not merely around the palpable abnormality.
• Symmetric, comparable positioning of the contralateral side whenever bilateral comparison is anticipated (Section 3.1).
• Comfort strategies: patients with an acute infective or inflammatory process, or a painful post-traumatic collection, may not tolerate a long protocol; sequence prioritisation (Section 8) should be planned in advance.
• Common positioning errors: FOV centred tightly on the palpable abnormality with inadequate longitudinal margin, missing proximal/distal extension along the fascial plane; omission of a contralateral comparison sequence when one would materially aid interpretation; failure to confirm the specific fascial layer of clinical concern (superficial vs. deep) before planning slice orientation.

4. Standard Protocol Design

4.1 Mandatory Core Sequences

4.2 Conditional Sequences

• Diffusion-weighted imaging (DWI)/ADC mapping: contrast-independent adjunct, useful when contrast is contraindicated or as a complementary characterisation feature for a purulent collection or a cellular mass; not yet a mandatory component of the generic protocol.
• Contralateral comparison sequence (mirrored fluid-sensitive fat-suppressed sequence over the unaffected side): strongly recommended for suspected inflammatory/autoimmune fascial disease and for subtle or early infective change, where symmetry (or its absence) is itself diagnostically informative [3].
• Dedicated high-resolution sequence over a short segment of interest: useful once a specific, localized fascial abnormality has already been identified on the standard survey and finer anatomical detail (e.g., a discrete fascial defect underlying a muscle hernia) is required.

4.3 Rationale Summary Per Sequence

The non-fat-suppressed T1-weighted sequence provides the anatomical baseline against which fat content, subacute haemorrhage, and — critically — true post-contrast enhancement are subsequently judged; without it, apparent post-contrast "enhancement" cannot be reliably distinguished from intrinsic T1-hyperintensity. The fluid-sensitive fat-suppressed T2/STIR sequence is the single most important sequence on this page: it is the primary detection tool for fascial thickening, oedema, and fluid across all four disease categories, and omitting it is the single most consequential protocol error possible for a fascia-directed study. Post-contrast fat-suppressed T1 imaging, matched in geometry to a pre-contrast acquisition, is the principal discriminator between viable/hyperaemic and necrotic/avascular fascia, and between solid enhancing tissue and non-enhancing fluid — the decision that most directly changes management across infective and neoplastic indications.

4.4 Sequence Matching and Cross-Sequence Consistency

Pre- and post-contrast fat-suppressed T1 sequences must be acquired with matched geometry (identical slice positioning, thickness, and FOV) to permit reliable visual or subtraction-based comparison; mismatched geometry between the two materially degrades diagnostic confidence for the single most important discriminator in this protocol (Section 4.3) and is a recurring, avoidable error.

4.5 Fat Suppression — Central Technical Principle for Fascial Imaging

Because the fascia is, almost by definition, a thin structure embedded in and directly adjacent to fat, reliable and homogeneous fat suppression is not an optional refinement but a structural requirement of this protocol — inadequate fat suppression can either obscure genuine fascial signal change or, conversely, create a false impression of thickening or abnormal signal at a fat–fascia interface through incomplete or inhomogeneous suppression [4].

• Spectral (chemical-shift-selective) fat saturation is the default technique for post-contrast imaging, since it does not interact adversely with paramagnetic contrast the way inversion-recovery techniques can; it is however sensitive to magnetic field inhomogeneity, which is a genuine practical concern for off-isocentre limb or trunk regions [4].
• STIR (short-tau inversion recovery) provides more homogeneous, field-inhomogeneity-resistant fat suppression and is therefore preferred for off-isocentre anatomy or in the presence of field-inhomogeneity-prone regions, consistent with this platform's site-wide standard; STIR is, however, contraindicated on any post-contrast sequence, since gadolinium shortens T1 in a way that can paradoxically suppress genuinely enhancing tissue on an inversion-recovery-based sequence — spectral fat saturation or a Dixon-based technique must be used for all post-contrast imaging on this page, without exception [4].
• Dixon-based (chemical-shift/opposed-phase) techniques offer an increasingly used alternative that is comparatively robust to field inhomogeneity while remaining compatible with post-contrast imaging, and are a reasonable substitute for spectral fat saturation where locally available [4].
• Practical decision rule for this protocol: spectral fat saturation or Dixon-based technique as the default for post-contrast sequences everywhere on this page; STIR as the pre-contrast fallback specifically for off-isocentre or field-inhomogeneous anatomy; STIR never post-contrast.

4.6 Field of View and Coverage Principles for a Plane-Like Structure

Unlike a discrete organ or a joint, a fascial plane is a two-dimensional sheet that can extend for a considerable longitudinal distance, and disease along it — infective, inflammatory, or neoplastic — characteristically extends beyond the segment that is clinically or sonographically apparent. Practical consequences for FOV planning: (1) coverage should be generously bracketed beyond the palpable or visibly abnormal segment along the presumed long axis of the fascial plane, not restricted tightly to it; (2) where the fascial plane of concern crosses a joint or a named anatomical boundary (e.g., the thoracolumbar or gluteal fascia crossing toward the trunk), coverage should extend across that boundary rather than stopping at it by convention; (3) a narrow FOV strictly matched to the palpable margin is one of the most consequential and avoidable planning errors specific to fascial imaging, since it directly risks under-staging the longitudinal extent of disease — a factor central to surgical planning in every one of the four disease categories on this page.

5. Optimisation Strategy

5.1 Artifact Reduction by Source

• Susceptibility artefact near orthopaedic hardware: relevant when fascial imaging is requested after prior surgery or hardware placement; metal-artefact-reduction sequences should be anticipated and planned at referral where hardware is documented.
• Chemical shift artefact at fat–fascia interfaces: a direct consequence of the thin, fat-embedded nature of the normal fascia (Section 1.2); frequency-encoding direction should be planned to minimise displacement artefact across the fascial plane of interest where feasible.
• Motion artefact between matched pre- and post-contrast acquisitions: degrades the single most important comparison in this protocol (Section 4.3–4.4); patient comfort and analgesia planning (Section 3.2) directly reduces this risk.
• Field inhomogeneity at off-isocentre anatomy: the principal driver of the STIR-versus-spectral-fat-saturation decision in Section 4.5.

5.2 Field Strength Considerations

Higher field strength (3T) improves signal-to-noise for the thin fascial structures that are the primary target of this protocol, but increases susceptibility to chemical shift and field-inhomogeneity artefact — the same trade-off recognised generically for musculoskeletal imaging at 3T — reinforcing the fat-suppression technique selection logic in Section 4.5 rather than overriding it.

5.3 Coil and Positioning Strategy for Thin, Plane-Like Structures

Surface coil placement should prioritise close, even coverage along the anticipated fascial plane rather than simple anatomical centring on the palpable abnormality; where the region of interest crosses two conventional coil zones (e.g., hip-to-thigh fascial continuity), a combined or extended coil solution should be planned proactively rather than accepted as a coverage gap.

6. Contrast Use Principles Specific to Fascial Imaging

6.1 Non-Contrast Standard Protocol — Sufficient For

• An uncomplicated, clinically and sonographically characteristic Morel-Lavallée lesion without clinical concern for secondary infection.
• Follow-up imaging of a previously characterised, stable traumatic/mechanical fascial abnormality where a new enhancement-based question is not being asked.
• An initial screening study whose sole purpose is to confirm or exclude fascial-plane fluid or gross morphological abnormality, before a decision is made on whether contrast-enhanced characterisation is required.

6.2 Gadolinium Indicated — Context-Specific

• Any suspected infective process (cellulitis with uncertain deep extension, suspected fasciitis, post-surgical/post-traumatic infection): enhancement pattern is the principal discriminator between viable, hyperaemic tissue and necrotic or purulent, non-enhancing tissue.
• Suspected active inflammatory/autoimmune fascial disease: fascial enhancement is a recognised marker of disease activity in localized scleroderma/eosinophilic fasciitis-spectrum disease, distinct from the chronic, fibrotic, less avidly enhancing appearance of burned-out disease [3].
• Any fascia-based or fascia-associated mass: enhancement pattern contributes to the benign/malignant risk-stratification process, and discriminates solid tissue from cystic/necrotic or myxoid components.
• Any clinical scenario in which the differential explicitly includes a necrotizing process: while imaging must never delay surgical referral in a clinically convincing case (Section 2.2), when imaging is obtained, gadolinium-enhanced fat-suppressed T1 imaging is the sequence most directly informative for identifying non-enhancing (necrotic) fascia — see the dedicated necrotizing fasciitis child page for entity-specific interpretation.

6.3 Post-Contrast Acquisition Timing

Post-contrast fat-suppressed T1 imaging should be acquired promptly after contrast administration, with geometry matched exactly to the pre-contrast sequence (Section 4.4); where a specific enhancement-pattern question is being asked (e.g., discriminating a rim-enhancing collection from solid tissue), a single well-timed, well-matched acquisition is preferable to multiple mistimed or poorly matched ones.

7. Reporting Essentials

7.1 Interpretation Framework

A structured, generically applicable description of any fascial abnormality on this page should explicitly characterise: thickness (and, where a validated threshold exists for the specific entity in question, whether it exceeds that threshold — entity-specific thresholds belong to the dedicated child pages); signal characteristics on fluid-sensitive fat-suppressed sequences (homogeneous versus heterogeneous, including any low-signal component within an otherwise hyperintense abnormality); distribution and extent (focal versus diffuse, single versus multiple musculofascial compartments, superficial versus deep fascial layer); enhancement pattern (absent, uniform, irregular/mixed, or frankly non-enhancing within a background of otherwise abnormal signal); and relationship to adjacent structures (muscle, bone, neurovascular bundle, and — for trunk or cervical disease — proximity to deep anatomical spaces with a recognised risk of further tracking).

7.2 Mandatory Reporting Checklist

• Presence/absence of fascial thickening, with an explicit statement of which fascial layer (superficial, deep, or both) is involved.
• Signal characteristics on fluid-sensitive fat-suppressed sequences, including any focal low-signal component.
• Longitudinal extent along the fascial plane, explicitly stated relative to the FOV margins (i.e., whether the abnormality is fully contained within the study or appears to extend beyond it).
• Number of musculofascial compartments involved, where relevant to the clinical question.
• Presence, location, and character (simple fluid versus complex/loculated) of any associated fluid collection, distinguished from diffuse fascial signal change.
• Enhancement pattern, explicitly including whether any component is non-enhancing.
• An explicit statement of diagnostic confidence and its limitations, given the substantial overlap in fascial MRI appearance across the four disease categories on this page (Section 1.2) — avoid unqualified language ("this excludes/confirms [a specific diagnosis]") without reference to the clinical context and, where applicable, the entity-specific criteria on the relevant child page.
• An explicit recommendation regarding urgency for any finding raising concern for a necrotizing or rapidly progressive process, worded to support rather than substitute for ongoing clinical and surgical judgement.

7.3 Structured Reporting

Reports should separate description (what is seen) from interpretation (what it most likely represents, and the differential), explicitly naming the leading diagnostic category from Section 1 (traumatic/mechanical, infective, inflammatory/autoimmune, or neoplastic) wherever the pattern is sufficiently characteristic to do so, and explicitly declining to commit to a single category where the pattern remains genuinely non-specific.

7.4 Incidental Findings — Clinical Decision Framework

An incidentally noted, asymptomatic focus of mild fascial thickening or signal change, without a corresponding clinical question, should be described factually without being over-interpreted through the lens of any single disease category; a brief follow-up or clinical-correlation recommendation is generally more appropriate than an extensive differential diagnosis for a finding that was not the indication for the study.

8. MRI Technologist Pearls

8.1 Sequence Order Logic

Acquire the non-fat-suppressed T1-weighted sequence and the primary fluid-sensitive fat-suppressed T2/STIR sequence first, since these two sequences alone answer the majority of "is the fascia abnormal, and where" questions even if the study must be curtailed; place contrast-eligibility confirmation and the pre-contrast fat-suppressed T1 sequence before contrast injection, and acquire the matched post-contrast sequence immediately afterward without an intervening, differently positioned sequence.

8.2 Positioning Tricks

Mark the skin at the point of maximal clinical concern before the patient enters the bore, and confirm verbally with the patient (where possible) the exact location and character of any palpable abnormality; when a contralateral comparison is planned, position both sides as symmetrically as coil geometry allows before beginning acquisition, rather than attempting to correct positioning asymmetry retrospectively at the console.

8.3 Fast Salvage Protocol

If the study must be curtailed (patient intolerance, equipment time constraint, incidental contraindication discovered at the table), prioritise, in order: (1) the fluid-sensitive fat-suppressed T2/STIR sequence in the plane best demonstrating longitudinal extent; (2) the non-fat-suppressed T1-weighted sequence; (3) if contrast has already been administered, the matched post-contrast fat-suppressed T1 sequence takes priority over any remaining non-contrast sequence.

8.4 Common Avoidable Errors

9. Quality Control Checklist

• Full longitudinal coverage of the fascial plane of concern, with generous margin beyond the palpable or visible abnormality, confirmed before the patient leaves the scanner.
• Correct fascial layer(s) (superficial, deep, or both) explicitly addressed by the acquired sequences.
• Pre- and post-contrast fat-suppressed T1 sequences, where acquired, with matched geometry.
• STIR not used on any post-contrast sequence.
• No significant motion degradation, particularly of the matched pre-/post-contrast pair.
• Fat suppression homogeneous across the region of interest; technique substituted (STIR ↔ spectral/Dixon) where the primary choice proves inadequate.
• Contralateral comparison sequence present where clinically indicated (Section 4.2).
• Correct laterality and orientation labelling, verified against the request and the skin marker.
• Contrast administration and injection timing documented, where applicable.
• Comparison with prior studies performed where available.
• An explicit statement of urgency/next step present in the report draft for any finding raising concern for a necrotizing or rapidly progressive process, before the study is finalised.

10. Advanced Technical Parameters

T1-weighted spin-echo (non-fat-suppressed, pre-contrast)

• Tissue contrast logic: anatomical baseline; delineates the normal thin, low-signal fascial network against fat, and characterises T1-hyperintense content (fat, subacute blood, proteinaceous fluid) before contrast is given.
• Acquisition design: representative parameters TR ≈ 500–900 ms, TE ≈ 10–15 ms, slice thickness ≈ 3–5 mm, FOV tailored to the region and to the anticipated longitudinal extent of the fascial plane.
• Diagnostic advantages: anatomical roadmap; baseline for true-enhancement assessment; depicts fat and haemorrhage.
• Limitations: low intrinsic sensitivity to oedema and early inflammatory change; must always be paired with a fluid-sensitive sequence.
• Common artefacts: chemical shift at the fat–fascia interface, a direct consequence of the thin, fat-embedded normal anatomy described in Section 1.2.

Fluid-sensitive fat-suppressed T2/STIR (pre-contrast) — the primary detection sequence

• Tissue contrast logic: maximises conspicuity of fascial oedema, fluid, and thickening against suppressed-fat background; the single most sensitive sequence on this page for any of the four disease categories.
• Acquisition design: representative parameters TR ≈ 3,500–6,000 ms, TE ≈ 60–100 ms, slice thickness ≈ 3–5 mm; long-axis (coronal or sagittal) acquisition mandatory whenever longitudinal extent is a clinical question (Section 4.1).
• Diagnostic advantages: detects and roughly characterises fascial abnormality of essentially any aetiology; depicts extent along the fascial plane.
• Limitations: signal characteristics overlap substantially between the four disease categories; not by itself diagnostic of a specific entity (Section 1.2).
• Fat suppression role: mandatory; technique selection follows Section 4.5.

Pre- and post-contrast fat-suppressed T1-weighted — the principal discriminator on this page

• Tissue contrast logic: viable, hyperaemic fascia enhances; necrotic fascia, simple fluid, and most myxoid tissue does not (or enhances only faintly/peripherally); comparison against the matched pre-contrast baseline isolates true enhancement.
• Acquisition design: representative parameters TR ≈ 500–900 ms, TE ≈ 10–15 ms (or a comparable 3D spoiled gradient-echo fat-suppressed acquisition where department protocol favours 3D for post-contrast imaging), slice thickness and FOV matched exactly to the pre-contrast sequence.
• Diagnostic advantages: the principal discriminator between viable and non-viable (necrotic) fascia across the infective category, between active and burned-out disease in the inflammatory/autoimmune category, and between solid and non-solid/necrotic components in the neoplastic category.
• Limitations: enhancement pattern is not fully entity-specific; overlap exists particularly between active inflammatory disease and low-grade infective/reactive change.
• Common artefacts: incomplete fat suppression mimicking or masking enhancement; motion between pre- and post-contrast acquisitions degrading comparison; STIR-related paradoxical suppression if incorrectly used post-contrast (must be avoided, Section 4.5).
• 2D vs 3D: 2D multiplanar remains a robust default; 3D fat-suppressed spoiled gradient-echo acquisition is a reasonable, increasingly used alternative for larger or trunk-based regions, offering isotropic reformatting at some cost in acquisition time and, at 3T, SAR.

Diffusion-weighted imaging / ADC (adjunct)

• Tissue contrast logic: restricted diffusion in cellular tissue or purulent collections versus relatively free diffusion in simple fluid or myxoid tissue.
• Diagnostic advantages: contrast-independent adjunct characterisation, useful when contrast is contraindicated.
• Limitations: not yet standardised as a mandatory component of this generic protocol; susceptibility-related distortion can degrade image quality near metal or at tissue interfaces, which is a particular concern for the thin, interface-adjacent fascial structures that are the target of this page.

11. Evidence Gaps & Ongoing Debate

• Fascial thickness and signal thresholds validated for one disease category do not automatically generalise to another. The great majority of quantitative thresholds in the current literature (e.g., deep fascial thickness cut-offs) were derived specifically for necrotizing soft-tissue infection and have not been systematically re-validated across the inflammatory/autoimmune or neoplastic categories on this page; extrapolation should be made cautiously and is explicitly flagged wherever it occurs on the dedicated child pages.
• Comparative outcome evidence for STIR versus spectral versus Dixon-based fat suppression specific to fascial imaging (rather than musculoskeletal imaging in general) is limited; the practical decision rule in Section 4.5 is a reasonable, widely used default rather than a formally comparative-trial-validated recommendation for this specific application.
• Criteria for when a generic, regionally focused fascial study should be extended to a wider or bilateral comparative survey are largely based on expert practice rather than a validated, universally adopted threshold, particularly for the inflammatory/autoimmune category, where multifocal or symmetric involvement is common but not universal.
• The role of DWI/ADC as a routine, rather than adjunct, sequence for fascial characterisation across any of the four disease categories is promising in isolated reports but not yet established as mandatory.
• AI-assisted segmentation of thin, plane-like fascial structures is an active area of technical development but remains substantially less mature than segmentation of discrete organs or masses, given the inherent thinness and low baseline conspicuity of normal fascia (Section 1.2).

12. Evidence-Based References

A. Guidelines / Consensus / Society Recommendations

B. Systematic Reviews / Meta-analyses / Major Pictorial Reviews

C. Important Prospective / Original Studies

D. Technical MRI Papers

E. Landmark Historical References

End of document — MRI of Fascial Structures — Generic Standard Protocol — MRIninja Master Page v1.0 — August 2026